Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)21.25
  • Today's Change1.20 / 5.99%
  • Shares traded1.53m
  • 1 Year change-11.83%
  • Beta0.5201
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

  • Revenue in HKD (TTM)670.77m
  • Net income in HKD-953.77m
  • Incorporated2009
  • Employees1.49k
  • Location
    CanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
  • Phone+86 2 258213766
  • Fax+86 2 258213626
  • Websitehttp://www.cansinotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Recbio Technology Co Ltd0.00-603.67m4.30bn507.00--4.63-----1.26-1.260.001.920.00----0.00-25.33---32.84----------0.9619-60.960.4548------20.86------
Beijing Luzhu Biotechnology Co Ltd0.00-308.07m4.52bn148.00--4.38-----1.52-1.520.005.130.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Shandong Boan Biotechnology Co Ltd792.18m68.02m4.89bn813.0068.373.0333.866.170.13340.13341.563.010.30691.102.60974,387.102.63--3.43--74.10--8.59--1.034.010.3224--19.80--64.02------
Sihuan Pharmaceutical Holdings Group Ltd1.93bn-41.60m5.03bn2.65k--1.03--2.61-0.0045-0.00450.2080.5220.15060.96411.98672,300.30-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.52-1.390.181---14.70-8.6097.23--0.9325--
Consun Pharmaceutical Group Ltd3.01bn920.46m5.09bn3.18k5.281.255.051.691.141.143.744.820.52092.0011.77963,936.6015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
AIM Vaccine Co Ltd1.30bn-1.31bn5.12bn1.56k--1.33--3.93-1.08-1.081.083.180.14620.63251.10802,448.00-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Shanghai Fudan-Zhangjiang Bio-Pharm. Co809.99m121.78m5.72bn948.0015.230.7035--7.060.11560.11560.76162.500.25041.261.35854,424.103.757.034.669.0591.2592.1714.9717.263.78--0.005239.16-17.502.78-21.28-0.632620.49--
Tong Ren Tang Technologies Co Ltd7.57bn716.19m6.19bn4.01k8.640.79224.320.81740.55920.55925.916.100.50260.98815.221,845,461.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.29bn779.0012.741.6510.184.570.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
China Shineway Pharmaceutical Group Ltd4.63bn1.22bn6.50bn3.44k4.880.80514.671.401.611.616.139.760.44761.285.261,346,646.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.10bn1.81bn7.21bn4.89k3.970.75583.421.182.062.066.9310.840.42722.503.571,320,291.0011.698.0317.2711.8178.9079.9727.3720.801.9325.510.212615.8168.0820.182,501.2416.15-11.50--
Everest Medicines Ltd460.62m-1.16bn7.45bn520.00--1.51--16.17-3.60-3.601.4315.130.07565.233.221,066,239.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Cansino Biologics Inc670.77m-953.77m7.84bn1.49k--0.8896--11.69-3.86-3.862.7222.540.06761.280.8385448,974.00-10.15-4.27-13.73-5.6014.38---150.19-27.722.19--0.3028---66.52213.94-63.04--30.60--
Luye Pharma Group Ltd6.95bn847.89m11.36bn5.27k13.400.79296.661.640.22540.22541.853.810.2362.442.841,318,408.003.112.805.474.4568.7370.5313.1810.391.202.960.401611.822.703.50-11.94-16.39-14.05--
SSY Group Ltd6.47bn1.37bn11.39bn5.80k8.361.576.231.760.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
Data as of Sep 20 2024. Currency figures normalised to CanSino Biologics Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.05%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Sep 20243.49m2.63%
Bosera Asset Management Co., Ltd.as of 31 Dec 20231.49m1.12%
GF Fund Management Co., Ltd.as of 31 Dec 20231.28m0.96%
Huashang Fund Management Co., Ltd.as of 31 Dec 2023944.00k0.71%
BlackRock Fund Advisorsas of 05 Sep 2024896.20k0.68%
Capital Research & Management Co. (World Investors)as of 30 Jun 2024893.52k0.67%
UBS SDIC Fund Management Co., Ltd.as of 31 Dec 2023500.20k0.38%
China Asset Management Co., Ltd.as of 31 Dec 2023421.80k0.32%
Dimensional Fund Advisors LPas of 05 Sep 2024401.60k0.30%
China Universal Asset Management Co., Ltd.as of 31 Dec 2023368.20k0.28%
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.